PPD

NOVEMBER 9, 2023

Our dedicated, global and highly experienced cross-functional early development team is ready to support you through this journey. The partner you select for your early phase studies is critical in enabling you to achieve your overall development timeline efficiently and within budget.

Clinical Development 52

Clinical Development Drug Development Clinical Research Treatment 52

Fierce BioTech

JANUARY 10, 2025

AI loud for Life Sciences. This breakthrough has the potential to drive major advancements in areas such as clinical development, where companies seek to better understand which patients will or will not respond to a given treatment. Learn how Nebius enables cost-effective innovation. Click here to login.

Science 52

Science Clinical Development Treatment Research 52

Fierce BioTech

MAY 15, 2024

But many life sciences organizations still rely on complex legacy IT infrastructures and struggle to make sense of constantly growing amounts of sensitive, regulated data. On Demand Start Date Tue, 06/25/2024 - 14:00

Science 52

Science Clinical Development Regulations Research 52

Drug Target Review

FEBRUARY 10, 2025

Ive been involved in therapeutics development for over 25 years, working with small, medium, and large biotech companies. My focus has always been on advancing novel medicines from research to clinical development. We coordinate all these aspects for the company, enabling them to stay focused on their science and strategy.

Therapies 64

Therapies Treatment Engineering Clinical Trials 64

The Pharma Data

MARCH 27, 2021

Gilead Sciences, Inc. Nasdaq: GILD) today announced that Flavius Martin, MD will join the company as Executive Vice President, Research, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day.

Science 52

Science Research Clinical Development Pharmacy 52

The Pharma Data

JANUARY 14, 2021

PRA Health Sciences selected for the study which will position Awakn at the Forefront of Psychedelic Research for Addiction Treatment. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London and Chair of Awakn’s Scientific Advisory Board. About PRA Heath Sciences.

Science 52

Science Treatment Clinical Trials Trials 52

Drug Target Review

APRIL 3, 2024

Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences. Communication and networking are key in any career, with science being no exception.

Science 105

Science Clinical Development Treatment DNA 105

The Pharma Data

NOVEMBER 29, 2020

Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs. ” About Ascletis.

Clinical Development 40

Clinical Development Disease Clinical Trials Therapies 40

Drug Target Review

MARCH 17, 2025

He has contributed to more than 130 granted patents and advanced over 12 clinical drug candidates across various therapeutic areas, including cognition, depression, pain and other disorders. With over 25 years of experience in the pharmaceutical industry, Donello has been instrumental in drug discovery and development.

Treatment 52

Treatment Licensing Licensing Science 52

Cytel

NOVEMBER 8, 2023

Written by Natalia Muehlemann, Vice President, Clinical Development, and Ari Brettman, Senior Managing Director, Blackstone Life Sciences When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities.

Clinical Trials 59

Clinical Trials Trials Clinical Development Science 59

The Pharma Data

DECEMBER 23, 2020

The Company has Now Resumed the Clinical Development of its Proposed Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum. 24, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences Inc. On December 18, 2020 – The Company issued the following press release: “Tauriga Sciences Inc. Tauriga Sciences, Inc.

Science 52

Science Pharmaceuticals Clinical Development Production 52

Drug Target Review

AUGUST 28, 2024

Available from: [link] About the author Cliff Brass, MD PhD FAASLD, Chief Medical Officer at Resolution Therapeutics Cliff Brass is an expert in clinical development with special expertise in liver disease and over 25 years of experience in pharma. He is named on 15 patents relating to drug development in liver disease.

Therapies 116

Therapies Disease Engineering Medical Schools 116

PerkinElmer

JANUARY 25, 2023

Laboratory professionals in all areas of science have experienced significant changes in recent years, and 2022 was no exception. Experts in the diagnostics and life sciences industry look back on 2022 and lend their insights on the major trends and technologies shaping laboratories in 2023.

Science 52

Science Laboratories Immune Response Disease 52

The Pharma Data

MARCH 15, 2022

Global Head of Blackstone Life Sciences “We are excited to collaborate with Sanofi’s experienced development team to advance a subcutaneous dosage form for Sarclisa for patients. About Blackstone Life Sciences. Nicholas Galakatos, Ph.D. More information is provided at [link].

Science 52

Science Treatment Clinical Trials Therapies 52

The Pharma Data

FEBRUARY 24, 2022

About Bayer’s Commitment in Cardiovascular and Kidney Diseases Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments.

Clinical Development 52

Clinical Development Disease Therapies Treatment 52

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

The Pharma Data

JANUARY 31, 2021

–( BUSINESS WIRE )– Gilead Sciences, Inc. While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. About Gilead Sciences. Gilead Sciences, Inc.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

KIF1A

SEPTEMBER 30, 2023

This program will encourage therapeutic sponsors to communicate with FDA officials more regularly and as needed to improve their clinical development of gene- and cell-based therapies.

Disease 111

Disease FDA Clinical Trials Therapies 111

The Pharma Data

NOVEMBER 30, 2020

Shailubhai will provide updates on the Company’s proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences. About Tiziana Life Sciences. NEW YORK and LONDON, Dec. +44 (0)20 7495 2379.

Science 40

Science Clinical Trials Disease Clinical Development 40

The Pharma Data

JULY 29, 2021

Gilead Sciences, Inc. Our flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. econd Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury. Viral Diseases.

Science 52

Science Production Treatment FDA 52

Drug Target Review

SEPTEMBER 5, 2024

With all this experience, I was very excited to take on the CEO role for Alzinova, a company developing a vaccine and other treatments against Alzheimer’s disease. I have built up this biopharma company from being a university science focused company to a biopharma company with all skills and focused on drug development and partnering.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

Drug Target Review

FEBRUARY 29, 2024

From a very young age, I was drawn to science and medicine. This early exposure to bench science had a long-lasting impact. Through their own experiences, my mentors have helped me navigate what can be a trying course for women in science. I have had the fortune of strong mentorship from women in STEM.

Therapies 111

Therapies Disease Clinical Trials Science 111

Precision for Medicine

JUNE 26, 2023

Baseline Control’s expertise will become part of Project Farma, Precision for Medicine’s existing biomanufacturing strategy and execution group, expanding the scope of its manufacturing solutions for life science companies and driving greater speed and efficiency in bringing new drugs to market.

Science 40

Science Small Molecule Clinical Research Engineering 40

Drug Target Review

JULY 18, 2023

AI is being used to find the targets themselves, design the drugs to manipulate that biology, and thirdly, AI is being used to support validation of those targets and drugs as part of pre-clinical development. Pharmaceutical companies are an absolutely pivotal part of the life sciences industry and ecosystem.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

The Pharma Data

DECEMBER 13, 2020

Hummingbird Bioscience is an innovative clinical-stage biotech company focused on developing revolutionary therapies against hard-to-drug targets for improved treatment outcomes. Our highly experienced teams in Singapore and the US span antibody discovery, pharmacology, production and clinical development.

Clinical Development 40

Clinical Development Clinical Trials Therapies Trials 40

Drug Target Review

DECEMBER 27, 2023

Aside from CD24, there are several other ‘don’t eat me’ signals that have been characterised, and there are multiple programmes currently in clinical development that target these signals. The potential of FcγRIIB in immunotherapy Are there other ‘don’t eat me’ signals that are known to play a role in cancer immune evasion?

Immune Response 105

Immune Response Science Clinical Development Drugs 105

Sygnature Discovery

JANUARY 26, 2024

Leveraging years of experience, we efficiently advance your compounds through preclinical studies and reduce risks as you move into clinical development. Our talented team of scientists can assist you in crafting robust pre-clinical development strategies.

Process Chemistry 52

Process Chemistry Pharmacokinetics Clinical Development Laboratories 52

The Pharma Data

JANUARY 26, 2021

27, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces that it has filed a “universal” shelf registration statement on Form F-3 (File No. About Tiziana Life Sciences.

Science 40

Science Disease Clinical Development Marketing 40

Drug Target Review

OCTOBER 1, 2024

I am sure new therapies will positively affect women around the world and will hopefully inspire more women to get involved in science and technology. In my opinion, the need to celebrate it highlights what any woman and scientist knows very well: there are not enough women in science yet. Gender equality, even in science, is crucial.

Doctors 97

Doctors Therapies Science Pharma Companies 97

Broad Institute

OCTOBER 11, 2023

The researchers soon partnered with Calico Life Sciences , which in collaboration with AbbVie , discovered drug candidates that block the PTPN2 protein. By early 2021, Calico and AbbVie had launched two early-stage clinical trials testing two PTPN2 inhibitors, either as a single therapy or in combination with existing PD-1 immunotherapies.

Research 137

Research Immune Response Clinical Trials Therapies 137

Drug Target Review

FEBRUARY 1, 2024

In other cases, well-established biomarker profiles enable patient enrichment strategies in early-stage clinical development. Neurvati’s model can be characterised as a private equity model for neurotherapeutics development. And, how do you think it compares to other models as well?

Therapies 104

Therapies Drug Development Disease Clinical Development 104

NIH Director's Blog: Drug Development

SEPTEMBER 26, 2019

Science Translational Medicine, 2019 Researchers continue to produce impressive miniature human tissues that resemble the structure of a range of human organs, including the livers, kidneys, hearts, and even the brain. As published in Science Translational Medicine , they more than met the challenge. Credit: McAleer et al.,

Drugs 72

Drugs Science Treatment Clinical Trials 72

The Pharma Data

OCTOBER 6, 2021

1] This research builds on Johnson & Johnson’s work to advance science against emerging and entrenched global public health threats. Janssen is now moving its dengue program into clinical development. We are hopeful that this early-stage science can ultimately translate into a meaningful difference for at risk communities.

Virus 52

Virus Clinical Development Science Disease 52

KIF1A

MARCH 16, 2024

While genetic disorders like KAND make up only a small part of this number, this represents the need for increased investment in neuroscience research and clinical development. This is even more true for neurological disorders; according to a recent study by The Lancet , approximately 3.4

Disease 105

Disease Clinical Development Research Treatment 105

Fierce BioTech

AUGUST 25, 2023

Your Comprehensive Guide to Analytical Testing, From Clinical to Commercial pesurya Fri, 08/25/2023 - 10:45 Tue, 10/03/2023 - 11:00 Resource Type Webinar Katie Schlipp Elliott Franco, Ph.D. Duration 60 Minutes The life science industry has been growing rapidly, primarily driven by the rise of aging population and innovation in new modalities.

Small Molecule 52

Small Molecule Clinical Development Science Treatment 52

LifeSciVC

JULY 11, 2023

Redig, SVP and Head of Clinical Development at HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The American Cancer Society for Oncology (ASCO) annual meeting is among the highlights of the clinical oncology calendar. By Amanda J. His remarks are worth reading in their entirety.

Therapies 66

Therapies Trials Clinical Development Science 66

Drug Target Review

OCTOBER 16, 2024

I’ve always been drawn to the early stages of scientific discovery, where hypotheses are formed and developed into something tangible that can benefit patients. Being involved in these formative stages allows you to not only understand the challenges ahead but also shape the science to ensure it addresses patient needs.

Clinical Development 52

Clinical Development Drug Development Therapies Disease 52